A trial to assess the effects of denosumab on infection risk in patients with rheumatoid arthritis when administered with and without concurrent biologic therapy

Trial Profile

A trial to assess the effects of denosumab on infection risk in patients with rheumatoid arthritis when administered with and without concurrent biologic therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs Denosumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Aug 2015 New trial record
    • 10 Jun 2015 Primary endpoint 'risk of infection' has not been met according to results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 10 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top